Holen Sie sich die Stockscreener-App
5.50
0.73%
0.04
Vorhandelsmarkt:
5.48
-0.02
-0.36%
Schlusskurs vom Vortag:
$5.46
Offen:
$5.57
24-Stunden-Volumen:
443.24K
Relative Volume:
0.58
Marktkapitalisierung:
$274.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-122.31M
KGV:
-1.2181
EPS:
-4.5151
Netto-Cashflow:
$-110.41M
1W Leistung:
+4.76%
1M Leistung:
+18.53%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.43
$5.57
1-Wochen-Bereich:
$5.10
$5.65
52-Wochen-Spanne:
$4.29
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Firmenname
Helus Pharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
5.50 | 272.42M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Jefferies | Buy |
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Helus Pharma Inc Aktie (HELP) Neueste Nachrichten
Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN
HELP Initiated Coverage by TD Cowen -- Price Target Set at $8 - GuruFocus
Helus Pharma stock initiated at Buy by TD Cowen on MDD data - Investing.com Canada
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - ADVFN
symbol__ Stock Quote Price and Forecast - CNN
Cybin Inc (NASDAQ:HELP) - intelligentinvestor.com.au
HELP Should I Buy - Intellectia AI
HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill
Millennium Management LLC Increases Stake in Helus Pharma Inc - GuruFocus
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data - Insider Monkey
5 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
Helus Pharma appoints Michael Cola as CEO - MSN
Help stock crashes on anxiety trial results, but here’s why Jefferies sees up to 200% upside - MSN
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment - MSN
Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - Bitget
Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances - TipRanks
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment - Baystreet.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data - Yahoo Finance
Assessing Cybin (HELP) Valuation After HLP004 Phase 2 Anxiety Data Draws Fresh Attention - simplywall.st
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results - Yahoo Finance
Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact? - Yahoo Finance
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Sahm
Could Helus Pharma’s HLP004 Data Quietly Reframe Cybin’s (HELP) Interventional Psychiatry Investment Story? - simplywall.st
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Asianet Newsable
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
Helus Pharma’s top-line Phase II data signal detection study for HLP004 - The Pharma Letter
Jefferies reiterates Helus Pharma stock rating on anxiety data By Investing.com - Investing.com Canada
Agencia de ComunicacãoHelus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Estadão Blue Studio
Helus Pharma Stock Tumbles As Anxiety Drug Study DisappointsHelus Pharma (NASDAQ:HELP) - Benzinga
Finanzdaten der Helus Pharma Inc-Aktie (HELP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):